伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. It is set to report its Q3 ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

On Thursday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $189.65 which represents a slight increase of $1.77 or 0.94% from the prior close of $187.88. The stock opened at $188.43 ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...